Longitude Capital

Longitude Capital specializes in making venture growth investments in biotechnology, medical technology, and health solutions companies that seek to improve clinical outcomes, enhance patient quality of life, and reduce the cost of care. We invest in both privately held and publicly traded companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $2 billion across six funds and demonstrated an ability to source, manage, and exit attractive investments across multiple market cycles.

Our venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile, and attractive expected returns within three to five years from initial investment.

Longitude Capital seeks to identify new investment opportunities by tapping into our broad network of industry relationships or through the execution of proprietary thematic research into emerging therapeutic areas or industry sub-sectors. We utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity and equity-linked instruments.

Following an initial investment, we work closely with our portfolio companies and syndicate partners to develop and implement strategic plans, achieve key operating objectives, build world-class teams, raise capital, and pursue liquidity opportunities in a manner that optimizes returns to key stakeholders.

Our company name was inspired by the Longitude Prize, a competition established by the British monarchy in 1714 to solve one of the greatest scientific problems of the day.